The first human trials of mRNA-based vaccines targeted against HIV began earlier this year. And these phase 1 studies are making encouraging progress with patient recruitment.
However, epidemiologists and virologists have recently voiced ‘cautious optimism’ about these vaccine candidates' success.
It is also essential to engage behavioral scientists early in vaccine development. Scientists must think about how to place biological solutions within prevailing social norms, stated an article written by Devi Leena Bose on May 16, 2022.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
